Health · Cancer Research
Merck and Moderna Say Personalized mRNA Vaccine Met Melanoma Trial Goal
A Phase 3 trial of intismeran autogene plus Keytruda reduced recurrence after surgery, the companies announced, but they have not released the size of the benefit.